Phenominer Database Results (54 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Record ID Study ID
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 27 14.0 d 1.06 5.5 in vivo visual assessment 0.0 70194 1301
DA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 10 100.0 % in vivo visual assessment 0.0 84879 1301
DA.PVG.1AV1-(D4Got126-D4Got136) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 14 19.0 d 1.18 4.4 in vivo visual assessment 0.0 84924 1301
DA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 18 14.8 d 0.75 3.2 in vivo visual assessment 0.0 84926 1301
DA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 9 14.4 d 0.73 2.2 in vivo visual assessment 0.0 84915 1301
DA.PVG.1AV1-(D4Rat62-D4Got136)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 12 75.0 % in vivo visual assessment 0.0 84882 1301
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 11 100.0 % in vivo visual assessment 0.0 84883 1301
DA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 11 55.0 % in vivo visual assessment 0.0 84889 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female  days 24 91.7 % in vivo visual assessment 0.0 84466 1301
DA.PVG.1AV1-(D4Rat155-Spr) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 12 13.7 d 0.43 1.5 in vivo visual assessment 0.0 70198 1301
DA.PVG.1AV1-(D4Mgh17-D4Rat56) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 7 100.0 % in vivo visual assessment 0.0 70199 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 27 96.3 % in vivo visual assessment 0.0 70188 1301
LEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 13 15.4 % in vivo visual assessment 0.0 70193 1301
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 11 13.3 d 0.54 1.8 in vivo visual assessment 0.0 84922 1301
DA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 9 22.0 % in vivo visual assessment 0.0 84876 1301
DA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 9 17.0 d 0.93 2.8 in vivo visual assessment 0.0 84900 1301
PVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 16 20.2 d 2.98 11.9 in vivo visual assessment 0.0 84910 1301
DA.PVG.1AV1-(D4Rat62-D4Got136)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 12 15.4 d 0.66 2.3 in vivo visual assessment 0.0 84921 1301
DA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 8 100.0 % in vivo visual assessment 0.0 84884 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 37 14.0 d 0.0 0.0 in vivo visual assessment 0.0 70202 1301
LEW.1AV1/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 12 0.0 % in vivo visual assessment 0.0 70189 1301
DA.LEW.1AV1-(D4Mgh17-D4Mgh21)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 14 0.0 % in vivo visual assessment 0.0 84873 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male  days 24 100.0 % in vivo visual assessment 0.0 84465 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male  days 24 14.6 d 1.39 6.8 in vivo visual assessment 0.0 84467 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 6 16.3 d 0.94 2.3 in vivo visual assessment 0.0 84472 1301
DA.PVG.1AV1-(D4Mgh17-D4Rat56) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 7 12.4 d 0.49 1.3 in vivo visual assessment 0.0 70200 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 37 5.0 % in vivo visual assessment 0.0 70201 1301
DA.PVG-(D4Rat141-D4Mgh11) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 30 10.0 % in vivo visual assessment 0.0 70191 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 5 100.0 % in vivo visual assessment 0.0 70192 1301
DA.PVG-(D4Rat141-D4Mgh11) post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 30 31.7 d 1.86 10.2 in vivo visual assessment 0.0 70195 1301
DA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 12 100.0 % in vivo visual assessment 0.0 84880 1301
LEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 13 16.0 d 0.0 0.0 in vivo visual assessment 0.0 84903 1301
DA.PVG.1AV1-(D4Rat203-D4Got130)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 11 14.9 d 1.03 3.4 in vivo visual assessment 0.0 84916 1301
DA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 10 12.6 d 0.32 1.0 in vivo visual assessment 0.0 84918 1301
DA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 12 13.0 d 0.38 1.3 in vivo visual assessment 0.0 84919 1301
DA.PVG.1AV1-(D4Got126-D4Rat203)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 7 12.7 d 0.45 1.2 in vivo visual assessment 0.0 84920 1301
DA.PVG.1AV1-(D4Got126-D4Got136) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 14 64.0 % in vivo visual assessment 0.0 84886 1301
DA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 18 89.0 % in vivo visual assessment 0.0 84892 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female  days 24 14.6 d 0.63 3.1 in vivo visual assessment 0.0 84468 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 6 100.0 % in vivo visual assessment 0.0 84470 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 5 12.2 d 0.18 0.4 in vivo visual assessment 0.0 70196 1301
DA.PVG.1AV1-(D4Rat155-Spr) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 12 25.0 % in vivo visual assessment 0.0 70197 1301
PVG.1AV1/Kini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 29 0.0 % in vivo visual assessment 0.0 70190 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 11 45.0 % in vivo visual assessment 0.0 84878 1301
DA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 8 14.4 d 1.73 4.9 in vivo visual assessment 0.0 84923 1301
DA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 11 17.2 d 1.63 5.4 in vivo visual assessment 0.0 84925 1301
PVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 16 68.8 % in vivo visual assessment 0.0 84872 1301
DA.PVG.1AV1-(D4Rat155-D4Rat84) percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 7 0.0 % in vivo visual assessment 0.0 84874 1301
DA.PVG.1AV1-(D4Rat203-D4Got130)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 11 100.0 % in vivo visual assessment 0.0 84877 1301
DA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 9 100.0 % in vivo visual assessment 0.0 84875 1301
DA.PVG.1AV1-(D4Got126-D4Rat203)/Kiru percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 7 43.0 % in vivo visual assessment 0.0 84881 1301
DA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiru post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 11 14.0 d 0.42 1.4 in vivo visual assessment 0.0 84917 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 15 93.0 % in vivo visual assessment 0.0 84469 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 15 14.9 d 1.52 5.9 in vivo visual assessment 0.0 84471 1301